On July 6, Abivax S.A. rose 5.74% overnight, trading at $155.04/share, with turnover of $1.27 million. The movement was driven by the formal closing of the company's expanded equity offering, which saw underwriters fully exercise their over-allotment option to purchase an additional 960,000 American Depositary Shares.

The full exercise increased gross proceeds to approximately $920 million from the initially priced $800 million, with net proceeds of about $874.1 million earmarked for potential US commercialization of obefazimod, clinical research on ulcerative colitis and Crohn's disease, and general corporate purposes. Notably, the offering size was raised twice — from an initial $600 million launch to $800 million at pricing, and ultimately to $920 million with the greenshoe — reflecting robust institutional demand. The stock continues to trade above the $125 offering price, underpinned by positive Phase 3 ABTECT Maintenance Part 2 data reported in late June that eliminated safety concerns around malignancy rates for obefazimod, supporting the company's planned NDA submission in Q4.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)